MSB to dispute FDA finding in Type A meeting, page-319

Hindsight will tell us that the FDA telegraphed to the market prior to the ODAC review that rem-L was unlikely to be approved with single arm trial data. The ODAC were influenced by the emotive testimony...except the hard arsed FDA fossil rep who kept asking Si the same question like he had his fingers in his ears or turned his hearing aid off every time answered his question yet again. We all should’ve smelled a filthy rat then & there. The only other theory is that the FDA blindsided Si completely and are engaged in a campaign of deliberate blocking of the MSc science. Lengthy delays are expensive, dilutive & disheartening. They can destroy a company over time. Si & his team are high functioning savvy practitioners..they’ll steer the Msb ship right.,,but the X factor is how long, how much & what degree of dilution ?